​Results of clinical trials
Treatment of oncological diseases using GA-40
The Region of Eastern Europe (2009-20013)

























































GA-40 has 8 powerful effects on the body. 

6 of those are attacks on cancer.

  1. GA-40 directly and selectively acts on cancer cells and cause their destruction via apoptosis.

  2. GA-40 directly acts on Human Myeloid Leukemic cells and induces their differentiation into mature normal Myeloid cells.

  3. Ga-40 directly acts on peripheral blood mononuclear cells and causes their activation and the subsequent secretion of tumor necrosis factor (TNF) and interferon (INF-Y). These cytokines causes destruction of cancer cells via apoptosis.

  4. GA-40 directly acts and activates cytotoxic-T cells, cytotoxic macrophages and cytotoxic neutrophils. These cytotoxic cells recognize, surround and destroy cancer cells.

  5. GA-40 indirectly activates Natural killer Cells. These NK-cells recognize, surround and destroy cancer cells.

  6. GA-40 is anti-angiogenesis factor, reduces the level of the vascular epithelial cell growth factor (VEGF) in the blood. Inhibits formation of new blood vessels in tumor, inhibits tumor growth and prevents spread of metastases in the body via blood circulatory system by blocking tumor angiogenesis.

  7. GA-40 causes activation of macrophages and neutrophils phagocytosis, which promotes neutralization and elimination of destroyed tumor fragments and prevents intoxication of the organism.

  8. GA-40 shows anti-oxidant activity and thus causes neutralization of free radicals in the body, decrease intoxication and side effects caused by the treatment of chemo and radiotherapy.

GA-40 has no side effect, no contraindications and accordingly is completely harmless for the patients.
First stage: monotherapy with GA-40 when the size of tumor is not more than 1 cm, causing a complete regression of the tumor. If the tumor size over 1 cm, permanent and long-term monotherapy with GA-40 or in combination with chemo/radiotherapy before surgery provides the regression of the latent metastasis, reduced growth of primary tumor, stabilization and partial reduction in size. This treatment ensures the transfer of patients in operable condition, when with high probability exclude the occurrence of relapses. The monotherapy GA-40 after surgery virtually eliminates recurrences.
The second and third stages: monotherapy with GA-40 or in combination with chemo or radio therapy causes complete regression of latent and fixed metastasis, a suspension of growth of a primary tumor and partial regression, localization and translation of the patient in operable condition. Permanent and long-term monotherapy (or in combination with chemo - and radiotherapy) in most cases causes complete regression of the tumor and complete recovery.
Fourth stage: in cases of patients with advanced, incurable cancer (4 st., when the patient is refused all conventional methods of cure), prolonged application of GA-40 improve of quality of life and life extension.

Medical & Biological Scientific - Research Center“ALEXIS” LTD

© Alexis ltd. 2015. All Rights Reserved. The use of the information on this site is subject to the terms of our Legal Notice. This site is published by Alexis ltd, which is solely responsible for its contents. Product names are trademarks of Alexis ltd. This information is intended for use by our customers, patients, and healthcare professionals. Alexis ltd recognizes that the internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside Georgia.